CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lu+86 185 2048 1969kaka@cato-chem.com
Everolimus

依维莫司 杂质对照品Everolimus Impurities

EP25 个杂质条目25 impurity entries

本页汇总 依维莫司 的 25 个杂质对照品条目,其中药典杂质标注了 EP/USP 编号。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 25 impurity reference standards of Everolimus with EP/USP numbering where applicable. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

相关研究文献Related literature

以下为 依维莫司(Everolimus)在公开文献中的研究报道(题录信息,来源 PubMed),供方法开发与文献调研参考。Selected peer-reviewed publications on this drug substance — bibliographic records from PubMed.

  1. 杂质研究Impurity studiesDevelopment and Validation of Stability-indicating High Performance Liquid Chromatographic Method for the Estimation of Everolimus in Tablets
    Indian journal of pharmaceutical sciences · 2015 · Sharmila D et al.  ·  PMID 26798176  ·  DOI
  2. 杂质研究Impurity studiesUV-visible spectroscopy as an alternative to liquid chromatography for determination of everolimus in surfactant-containing dissolution media: a useful approach based on solid-phase extraction
    Journal of pharmaceutical and biomedical analysis · 2012 · Kamberi M, Tran TN  ·  PMID 22726455  ·  DOI
  3. 分析方法Analytical MethodsDevelopment and validation of an analytical method using UPLC-MS/MS to quantify everolimus in dried blood spots in the oncology setting
    Journal of pharmaceutical and biomedical analysis · 2018 · Knapen LM et al.  ·  PMID 29112898  ·  DOI
  4. 分析方法Analytical MethodsSimultaneous quantification of cyclosporin, tacrolimus, sirolimus and everolimus in whole blood by UHPLC-MS/MS for therapeutic drug monitoring
    Biomedical chromatography : BMC · 2021 · Antunes NJ et al.  ·  PMID 33462848  ·  DOI
  5. 分析方法Analytical MethodsDevelopment and validation of a simple and versatile method for the quantification of everolimus loaded in H-ferritin nanocages using UHPLC-MS/MS
    Journal of pharmaceutical and biomedical analysis · 2020 · Sottani C et al.  ·  PMID 32987250  ·  DOI

依维莫司 —— 原料药与杂质对照品Everolimus — drug substance & impurities

共 26 个条目(含原料药本体)26 items incl. the drug substance
Everolimus structure
EP原料药 APIAPI
依维莫司Everolimus
Everolimus
CAS No.159351-69-6
Chemical FormulaC53H83NO14
Purity>95%询价On request
10mg25mg50mg100mg
Everolimus Impurity 17(502-95)(Everolimus EP Impurity A) structure
EPA
依维莫司杂质17(502-95)(依维莫司EP杂质A)Everolimus Impurity 17(502-95)(Everolimus EP Impurity A)
Everolimus Impurity 17(502-95)(Everolimus EP Impurity A)
CAS No.53123-88-9
Chemical FormulaC51H79NO13
Purity>95%询价On request
10mg25mg50mg100mg
Everolimus Impurity 4 (Everolimus EP Impurity B) (804-95) structure
EPB
依维莫司杂质4 (依维莫司EP杂质B) (804-95)Everolimus Impurity 4 (Everolimus EP Impurity B) (804-95)
Everolimus Impurity 4 (Everolimus EP Impurity B) (804-95)
CAS No.1062122-63-7
Chemical FormulaC53H83NO14
Purity>95%询价On request
10mg25mg50mg100mg
Everolimus Impurity 7 (Everolimus EP Impurity D) (009-96) structure
EPD
依维莫司杂质7 (依维莫司EP杂质D) (009-96)Everolimus Impurity 7 (Everolimus EP Impurity D) (009-96)
Everolimus Impurity 7 (Everolimus EP Impurity D) (009-96)
CAS No.2760174-96-5
Chemical FormulaC53H83NO14
Purity>95%询价On request
10mg25mg50mg100mg
Everolimus Impurity 1 structure
1
依维莫司杂质1Everolimus Impurity 1
Everolimus Impurity 1
CAS No.745779-75-3
Chemical FormulaC52H81NO14
Purity>95%现货In stock
10mg25mg50mg100mg
Everolimus Impurity 2 (012-99) structure
2
依维莫司杂质2 (012-99)Everolimus Impurity 2 (012-99)
Everolimus Impurity 2 (012-99)
CAS No.1708118-13-1
Chemical FormulaC53H83NO14
Purity>95%询价On request
10mg25mg50mg100mg
Everolimus Impurity 3(013-99) structure
3
依维莫司杂质3(013-99)Everolimus Impurity 3(013-99)
Everolimus Impurity 3(013-99)
CAS No.147438-30-0
Chemical FormulaC32H49NO9
Purity>95%询价On request
10mg25mg50mg100mg
Everolimus Impurity 6 (008-96) structure
6
依维莫司杂质6 (008-96)Everolimus Impurity 6 (008-96)
Everolimus Impurity 6 (008-96)
CAS No.1704711-12-5
Chemical FormulaC54H85NO14
Purity>95%询价On request
10mg25mg50mg100mg
Everolimus Impurity 9 structure
9
依维莫司杂质9Everolimus Impurity 9
Everolimus Impurity 9
CAS No.159351-68-5
Chemical FormulaC59H97NO14Si
Purity>95%询价On request
10mg25mg50mg100mg
Everolimus Impurity 12 structure
12
依维莫司杂质12Everolimus Impurity 12
Everolimus Impurity 12
CAS No.164162-36-1
Chemical FormulaC9H19F3O4SSi
Purity>95%询价On request
10mg25mg50mg100mg
Everolimus Impurity 14(018-00) structure
14
依维莫司杂质14(018-00)Everolimus Impurity 14(018-00)
Everolimus Impurity 14(018-00)
CAS No.2607-52-5
Chemical FormulaC15H22O
Purity>95%询价On request
10mg25mg50mg100mg
Everolimus Impurity 24(Everolimus-d4) structure
24
依维莫司杂质24(依维莫司-d4)Everolimus Impurity 24(Everolimus-d4)
Everolimus Impurity 24(Everolimus-d4)
CAS No.1338452-54-2
Chemical FormulaC53H79D4NO14
Purity>95%询价On request
Everolimus Impurity 26 structure
26
依维莫司杂质26Everolimus Impurity 26
Everolimus Impurity 26
CAS No.108286-01-7
Chemical FormulaC3H5F3O4S
Purity>95%询价On request
10mg25mg50mg100mg
Everolimus Impurity 27 structure
27
依维莫司杂质27Everolimus Impurity 27
Everolimus Impurity 27
CAS No.18928-34-2
Chemical FormulaC4H4F6O6S2
Purity>95%询价On request
10mg25mg50mg100mg
Everolimus Impurity 28 structure
28
依维莫司杂质28Everolimus Impurity 28
Everolimus Impurity 28
CAS No.102229-10-7
Chemical FormulaC8H20O2Si
Purity>95%现货In stock
10mg25mg50mg100mg
Everolimus Impurity 31 structure
31
依维莫司杂质31Everolimus Impurity 31
Everolimus Impurity 31
CAS No.66548-22-9
Chemical FormulaC14H34O2Si2
Purity>95%询价On request
10mg25mg50mg100mg
Everolimus Impurity 35 structure
35
依维莫司杂质35Everolimus Impurity 35
Everolimus Impurity 35
CAS No.1620-98-0
Chemical FormulaC15H22O2
Purity>95%询价On request
10mg25mg50mg100mg
Everolimus Impurity 36 structure
36
依维莫司杂质36Everolimus Impurity 36
Everolimus Impurity 36
CAS No.88-26-6
Chemical FormulaC15H24O2
Purity>95%询价On request
10mg25mg50mg100mg
Everolimus Impurity 40 structure
40
依维莫司杂质40Everolimus Impurity 40
Everolimus Impurity 40
CAS No.69739-34-0
Chemical FormulaC7H15F3O3SSi
Purity>95%询价On request
10mg25mg50mg100mg
Everolimus Impurity 43 structure
43
依维莫司杂质43Everolimus Impurity 43
Everolimus Impurity 43
CAS No.851536-75-9
Chemical FormulaC55H87NO14
Purity>95%询价On request
10mg25mg50mg100mg
Everolimus Impurity 45 structure
45
依维莫司杂质45Everolimus Impurity 45
Everolimus Impurity 45
CAS No.2839144-81-7
Chemical FormulaC104H160N2O26
Purity>95%询价On request
10mg25mg50mg100mg
Everolimus Impurity 46 structure
46
依维莫司杂质46Everolimus Impurity 46
Everolimus Impurity 46
CAS No.489-01-0
Chemical FormulaC15H24O2
Purity>95%询价On request
10mg25mg50mg100mg
Everolimus Impurity 59 structure
59
依维莫司杂质59Everolimus Impurity 59
Everolimus Impurity 59
CAS No.908340-97-6
Chemical FormulaC53H83NO14
Purity>95%询价On request
10mg25mg50mg100mg
Everolimus Impurity 60 structure
60
依维莫司杂质60Everolimus Impurity 60
Everolimus Impurity 60
CAS No.19263-36-6
Chemical FormulaC16H24O
Purity>95%询价On request
10mg25mg50mg100mg
Everolimus Impurity 62 structure
62
依维莫司杂质62Everolimus Impurity 62
Everolimus Impurity 62
CAS No.1062121-67-8
Chemical FormulaC53H83NO15
Purity>95%询价On request
10mg25mg50mg100mg
Everolimus Impurity 9-d4 structure
9-D4
依维莫司杂质9-d4Everolimus Impurity 9-d4
Everolimus Impurity 9-d4
CAS No.1356839-88-7
Chemical FormulaC59H93D4NO14Si
Purity>95%询价On request

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

Literature & synthesis

依维莫司 —— 研究文献与合成路线Everolimus — literature & synthetic routes

以下题录由公开学术数据库按品种名检索汇总,供 依维莫司 的杂质谱研究、分析方法开发与工艺路线选择参考。文献题名与专利标题均可点击查看原文,版权归原作者与出版方所有。Citations below are aggregated from public scholarly databases by drug-substance name, for reference in impurity profiling, analytical method development and route selection for Everolimus. Titles link to the original records; copyright remains with the authors and publishers.

杂质与降解研究文献Impurity & degradation studies

  1. Echogenicity as a surrogate for bioresorbable everolimus-eluting scaffold degradation: analysis at 1-, 3-, 6-, 12- 18, 24-, 30-, 36- and 42-month follow-up in a porcine model
    Campos CM, Ishibashi Y, Eggermont J, et al. · The international journal of cardiovascular imaging · 2015 · 被引 25cited 25
  2. Diminished DYRK2 sensitizes hormone receptor-positive breast cancer to everolimus by the escape from degrading mTOR
    Mimoto R, Nihira NT, Hirooka S, et al. · Cancer letters · 2017 · 被引 18cited 18
  3. Evaluation of a novel commercial assay for the determination of cyclosporine A, tacrolimus, sirolimus, and everolimus by liquid chromatography-tandem mass spectrometric assay
    Becker S, Thiery J, Ceglarek U · Therapeutic drug monitoring · 2013 · 被引 21cited 21
  4. Evaluation of QMS everolimus assay using Hitachi 917 Analyzer: comparison with liquid chromatography/mass spectrometry
    Dasgupta A, Davis B, Chow L · Therapeutic drug monitoring · 2011 · 被引 19cited 19
  5. Determination of cyclosporine, tacrolimus, sirolimus and everolimus by liquid chromatography coupled to electrospray ionization and tandem mass spectrometry: assessment of matrix effects and assay performance
    Vethe NT, Gjerdalen LC, Bergan S · Scandinavian journal of clinical and laboratory investigation · 2010 · 被引 18cited 18
  6. Comparison of the Innofluor certican assay with HPLC-UV for the determination of everolimus concentrations in heart transplantation
    Baldelli S, Crippa A, Gabrieli R, et al. · Clinical biochemistry · 2006 · 被引 17cited 17

合成路线文献Synthetic-route papers

  1. Synthesis and evaluation of an injectable everolimus prodrug
    Wang H, Zheng X, Cai Z, et al. · Bioorganic & medicinal chemistry letters · 2017
  2. Everolimus delayed and suppressed cytomegalovirus DNA synthesis, spread of the infection, and alleviated cytomegalovirus infection
    Tan L, Sato N, Shiraki A, et al. · Antiviral research · 2019
  3. The mammalian target of rapamycin inhibitor everolimus suppresses proliferation, metabolic activity and collagen synthesis of human fibroblasts in vitro and exerts antifibrogenic effects in vivo
    Böhm M, Stegemann A, Metze D, et al. · The British journal of dermatology · 2017

题录与链接来自公开数据库 Europe PMC(含 PubMed 与全球专利题录)与 WIPO PatentScope,本站仅提供索引,不转载正文;如链接失效请以数据库检索为准。Citations are indexed from public databases (Europe PMC incl. PubMed and patent records, WIPO PatentScope); we provide links only and do not reproduce full text.

For formulation & analytical R&D

依维莫司 杂质谱研究要点Everolimus — impurity profiling notes

下面这些是拿到 依维莫司 的 26 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 26 impurity entries for Everolimus, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

本品种含药典编号杂质(EP/USP)。申报时药典已收载的杂质通常需要逐项对照,建议优先备齐药典编号对照品,再补充工艺与降解杂质。This drug substance includes pharmacopoeially designated impurities (EP/USP). Monographed impurities normally need item-by-item comparison during filing, so secure the pharmacopoeial standards first, then fill in process and degradation impurities.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances